Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email

Anixa recruits more urology centers for study of prostate cancer blood test

By LabPulse.com staff writers

November 25, 2019 -- Anixa Biosciences announced that the Urology Centers of Alabama (UCA) and the Idaho Urologic Institute will join other providers in testing and validating its Cchek prostate cancer confirmation liquid biopsy test.

The company's Cchek platform measures immune system cells in peripheral blood. Anixa said it has been tested for a role in the detection of 20 different solid tumors, including cancers of the prostate and breast. Prostate cancer is the lead application of the technology.

Homewood, AL-based UCA's 160-member staff includes 24 urologists, a medical oncologist, and a pathologist. The Idaho Urologic Institute has an advanced prostate cancer program and a full-service reference lab, with offices in Boise, Meridian, and Nampa.

Anixa plans to launch the Cchek test for prostate cancer at the end of this year.

Hormones in blood signal risk for prostate cancer
A higher level of insulin-like growth factor 1 in healthy men was associated with subsequent diagnosis and death from prostate cancer in a new prospective...
Cleveland Diagnostics' prostate cancer blood test gets breakthrough status
Cleveland Diagnostics' IsoPSA blood test for prostate cancer has been designated by the U.S. Food and Drug Administration as a breakthrough device, which...
BRCA status leads the way in screening men for prostate cancer
Blood testing for levels of prostate-specific antigen gets a bad rap, but a targeted approach is gaining support. A large study published online September...
Urologic pathologist hops aboard OncoCell MDx
Urologic pathology specialist Dr. Kirk Wojno is now the chief medical officer at OncoCell MDx, a privately held company that is developing noninvasive,...
Urine test may help profile prostate tumors
The use of genetic risk signatures derived from urine test analyses looks promising for differentiating aggressive versus indolent types of prostate cancer,...

Copyright © 2019 LabPulse.com

Last Updated np 11/22/2019 3:46:54 PM